期刊文献+

初发急性早幼粒细胞白血病采取凝血指标检测的临床价值研究 被引量:2

下载PDF
导出
摘要 目的探讨初发急性早幼粒细胞白血病采取凝血指标检测的临床价值。方法选取30例初发急性早幼粒细胞白血病患者作为初发急性早幼粒细胞白血病组,根据根据病情的严重程度不同分为高危组(5例)、中危组(15例)及低危组(10例);根据是否并发弥漫性血管内凝血分为并发组与非并发组,各15例。选取30例非初发急性早幼粒细胞白血病患者作为非初发急性早幼粒细胞白血病组;另选取健康体检者60例作为对照组。比较各组凝血指标[凝血酶原时间(PT)、活化部分凝血活酶时间(APTT)、纤维蛋白原(FIB)、凝血酶时间(TT)和D-二聚体]水平。结果初发急性早幼粒细胞白血病组和非初发急性早幼粒细胞白血病组的PT长于对照组,D-二聚体高于对照组,差异有统计学意义(P<0.05)。初发急性早幼粒细胞白血病组的PT长于非初发急性早幼粒细胞白血病组,D-二聚体高于非初发急性早幼粒细胞白血病组,差异有统计学意义(P<0.05)。初发急性早幼粒细胞白血病组FIB低于对照组和非初发急性早幼粒细胞白血病组,差异有统计学意义(P<0.05)。高危组的PT长于中危组、低危组,D-二聚体高于中危组、低危组,FIB低于中危组、低危组,差异有统计学意义(P<0.05);高危组与中危组、低危组的APTT、TT水平比较,差异无统计学意义(P>0.05)。并发组患者的PT(17.01±0.54)s长于非并发组的(13.20±0.53)s,D-二聚体(19121±131.21)μg/L高于非并发组的(17105±103.13)μg/L,FIB(1.24±1.11)g/L低于非并发组的(1.94±1.10)g/L,差异有统计学意义(P<0.05)。结论初发急性早幼粒细胞白血病患者PT升高与病情有关,高水平的PT、D-二聚体和低水平的FIB对初发急性早幼粒细胞白血病合并并发弥漫性血管内凝血具有早期诊断意义。
作者 金鑫
出处 《中国现代药物应用》 2021年第19期91-93,共3页 Chinese Journal of Modern Drug Application
  • 相关文献

参考文献10

二级参考文献71

  • 1李新,赵耀中,李妍,李增军,袁晓莉,邹德慧,杨仁池,韩明哲,王建祥,邱录贵.高白细胞急性早幼粒细胞白血病49例临床分析[J].中华血液学杂志,2006,27(3):205-207. 被引量:5
  • 2Zhu J, Koken MH, Quignon F, et al. Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia. Proc Natl Acad Sci U S A, 1997, 94: 3978- 3983.
  • 3Yedjou C, Tchounwou P, Jenkins J, et al. Basic mechanisms of arsenic trioxide (ATO)-induced apoptosis in human leukemia (HL-60) cells. J Hematol Oncol, 2010, 3: 28.
  • 4Soignet SL, Maslak P, Wang ZG, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med, 1998, 339: 1341-1348.
  • 5Warrell RP, Maslak P, Eardley A, et al. Treatment of acute promyelocytic leukemia with all-trans retinoic acid: an update of the New York experience. Leukemia, 1994, 8: 929-933.
  • 6Sanz MA, Martin G, Gonzalez M, et al. Risk-adapted treatment of acute promyelocytic leukemia with all-trans-retinoic acid and anthraeycline monochemotherapy: a muhicenter study by the PETHEMA group. Blood, 2004, 103: 12371-43.
  • 7Wang ZY, Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood, 2008, 111:2505-2515.
  • 8Fenaux P, Chastang C, Chevret S, et al. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood, 1999, 94:1192-1200.
  • 9Ades L, Chevret S, Raffoux E, et al. Is cytarabine useful in the treatment of acute promyelocytic leukemia? Results of a randomized trial from the European Acute Promyelocytic Leukemia Group. J Clin Oncol, 2006, 24:5703-5710.
  • 10Soignet SL, Frankel SR, Douer D, et al. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol, 2001, 19:3852-3860.

共引文献47

同被引文献24

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部